Sanofi signed a collaboration and license agreement with Evoq Therapeutics, gaining rights to Evoq’s NanoDisc dendritic cell technology in exchange for up to $500 million in milestones. Sanofi will lead all clinical development and global commercialization, while Evoq supplies the NanoDisc platform for autoimmune disease candidates. Evoq’s approach aims to selectively modulate dendritic cells to upregulate regulatory T cells and anti‑inflammatory cytokines. Sanofi said the deal strengthens its immunology pipeline following other recent acquisitions and collaborations; analysts will watch which indications receive priority and how NanoDisc performs in early human data given prior industry interest from Gilead and others.